Article Details

Novartis announces iptacopan met Phase II study primary endpoint in rare kidney disease IgA ...

Retrieved on: 2021-06-06 10:18:45

Tags for this article:

Click the tags to see associated articles and topics

Novartis announces iptacopan met Phase II study primary endpoint in rare kidney disease IgA .... View article details on hiswai:

Excerpt

Iptacopan is the most advanced asset in the company's nephrology pipeline and targets the alternative complement pathway, a key driver of ...

Article found on: pipelinereview.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up